Novartis News on Daylife

Scots denied stomach cancer drug

Tue, 08 Dec 2009 00:33:08 GMT

Your account has been frozen. For your available options click the below button. To read this article in full you must have registered and have a Premium Content Subscription with the The Scotsman site.
Source: Edinburgh Daily News

Second-Line CML Drugs Evoke Faster Response Than Front-Line Therapy

Mon, 07 Dec 2009 23:45:30 GMT

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson...
Source: RedOrbit

If You Like Dividends, You May Love These 8 Stocks

Mon, 07 Dec 2009 22:33:00 GMT

But don't take our word for it, or Barron's or Goldman's. The proof is in the pudding. As the rest of market goes sideways, dividend-paying stocks are continuing their upward trend this month. The iShares Dow Jones Select Dividend ETF [DVY Loading..
Source: CNBC

Novartis AG-Detailed Product Pipeline - research report released

Mon, 07 Dec 2009 21:10:40 GMT

Refer to a friend 2009-12-07 22:10:40 - Novartis AG-Detailed Product Pipeline - a new market research report on companiesandmarkets.com report also contains extensive information in tabular and graphical formats on a companys product...
Source: PR-Inside.com

Data from Three Phase II Trials to be Presented at the 51st American Society of Hematology Annual Meeting Demonstrate that INCB18424, a Selective JAK1/JAK2 Inhibitor, Has Potential in Multiple Hematology Conditions

Mon, 07 Dec 2009 19:05:22 GMT

WILMINGTON, Del.--(BUSINESS WIRE)--Dec 7, 2009 - Incyte Corporation (NASDAQ: INCY) announced this morning that INCB18424 (also referred to as INCB018424), its selective, orally available janus kinase (JAK) inhibitor, will be the subject of three...
Source: Drugs.com

Second-line CML drugs evoke faster response than front-line therapy

Mon, 07 Dec 2009 18:37:14 GMT

Oman to receive more vaccines in a week

Mon, 07 Dec 2009 06:57:39 GMT

(MENAFN - Times of Oman) The Sultanate is expected to receive the second batch of H1N1 vaccine in a week, according to authorities.
Source: Middle East North Africa Financial Network

Incyte pre-leukemia drug cuts symptoms

Mon, 07 Dec 2009 04:08:11 GMT

Incyte Corp.'s most advanced experimental drug reduced symptoms in patients with a disorder linked to acute leukemia, a study found.
Source: China Post

Quoted in 'Federal Circuit Transfers Patent Infringement Case out of the Eastern District of Texas'

Sat, 05 Dec 2009 04:34:23 GMT

said in Law.com:

There appears to be no connection between this case and the Eastern District of Texas except that in anticipation of this litigation, Novartis' counsel in California converted into electronic format 75,000 pages of documents ... and transferred them to the offices of its litigation counsel in Texas ... The assertion that these documents are 'Texas' documents is a fiction which appears to have been created to manipulate the propriety of venue.

Quoted in 'Novartis opens new flu vaccine plant in US'

Tue, 24 Nov 2009 20:09:38 GMT

Novartis said in Reuters Alert Net:

Cell culture technology for influenza vaccines is not yet approved in the United States; however, part of the HHS contract support for Holly Springs includes funding for the development of a flu cell culture vaccine

THE SMOKING GUN- Novartis recalled H1N1 vaccine two months before outbreak in Mexico

Sun, 19 Jul 2009 14:11:07 GMT

Photo from Getty Images by AFP/Getty Images

Tue, 19 May 2009 10:05:00 GMT

Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development specialist Klaus Stoehr wait before meeting with United Nations Secretary-General Ban Ki-moo...

Photo from AP Photo by Patrick Straub

Wed, 28 Jan 2009 00:00:00 GMT

Daniel Vasella, CEO Novartis, left, smiles next to Raymund Breu, Chief Financial Officer, right, during the 2008 full-year results press conference in Basel, Switzerland, Wednesday, Jan. 28, 2009.